We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VNA:XETRVonovia SE Analysis

Data as of 2026-06-11 - not real-time

€19.74

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Vonovia’s shares are trading at €19.74, comfortably below the 20‑day (€21.06) and 50‑day (€22.13) simple moving averages, confirming a bearish price trajectory. The 14‑day RSI sits at 31.5, indicating the stock is oversold and could be poised for a short‑term rebound. Technical momentum is still negative, with a bearish MACD histogram and price hovering just above the identified support level of €19.53. Resistance is anchored near €22.59, a barrier the market must clear to validate a sustained recovery. Volatility remains elevated at roughly 28.6% over the past month, suggesting sizable price swings in either direction.
On the valuation side, Vonovia trades at a trailing PE of 4.58 versus an industry average of over 33, and a price‑to‑book of 0.61, signaling deep discount relative to peers. The dividend yield of 6.26% coupled with a modest payout ratio of 28% points to a generous yet sustainable income stream. Cash generation is robust, with operating cash flow exceeding €2.2 bn and free cash flow near €2.0 bn, comfortably covering its interest obligations despite a debt‑to‑equity ratio above 120%. Recent earnings showed a 6.3% rise in adjusted EBITDA for the rental segment and a 30% surge in the value‑add business, reinforcing the company’s ability to grow earnings even as total revenue fell 33.8% year‑on‑year. Analysts’ consensus target prices average €30–€32, implying an upside of roughly 60% from current levels. However, the balance sheet is heavily leveraged, and regulatory pressures on German residential rents add a medium‑level headwind. In sum, the stock appears undervalued with attractive yield but carries notable debt and sector risks that merit cautious positioning.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support level
  • oversold RSI suggests bounce
  • bearish MACD indicates continued downside risk

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • significant valuation discount (PE 4.58, PB 0.61)
  • strong cash flow and sustainable dividend
  • target price upside >60%

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • high leverage and debt‑to‑equity ratio
  • regulatory rent‑control environment
  • stable dividend income

Key Metrics & Analysis

Financial Health

Revenue Growth-33.80%
Profit Margin57.94%
P/E Ratio4.6
ROE12.60%
ROA1.26%
Debt/Equity129.18
P/B Ratio0.6
Op. Cash Flow€2.2B
Free Cash Flow€2.0B
Industry P/E33.3

Technical Analysis

TrendBearish
RSI31.5
Support€19.53
Resistance€22.59
MA 20€21.06
MA 50€22.13
MA 200€24.76
MACDBearish
VolumeStable
Fear & Greed Index83.25

Valuation

Target Price€32.17
Upside/Downside63.03%
GradeUndervalued
TypeBlend
Dividend Yield6.26%

Risk Assessment

Beta0.35
Volatility28.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.